A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics

Trial Profile

A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs RP 3128 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Rhizen Pharmaceuticals
  • Most Recent Events

    • 01 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 01 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top